%0 Journal Article
%T Real-world effectiveness of long-acting antipsychotic treatments in a
nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder
and other diagnoses in Quebec
%A Emmanuel Stip
%A Jean Lachaine
%J Archive of "Therapeutic Advances in Psychopharmacology".
%D 2018
%R 10.1177/2045125318782694
%X Long-acting injectable antipsychotics (LAI-AP) for patients with schizophrenia (SCZ) have saved significant healthcare costs. However, the cost effectiveness of LAI-AP for patients with other mental disorders has yet to be established. The goal of this study was to evaluate the impact of early initiation of LAI-AP medications on healthcare resource utilization (HRU). Drawing on the Quebecois universal healthcare program (RAMQ), we conducted a nationwide prospective cohort study of LAI-AP under real-world conditions
%K antipsychotics
%K compliance
%K healthcare resource utilization
%K long-acting injection formulations of antipsychotics
%K relapse prevention
%K schizoaffective disorder
%K schizophrenia
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180377/